| Item type |
[ELS]学術雑誌論文 / Journal Article(1) |
| 公開日 |
2017-01-23 |
| タイトル |
|
|
タイトル |
Adoptive immunotherapy using autologous lymphocytes activated ex vivo with antigen stimulation for patients with incurable cancer |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 著者 |
Okawaki, Makoto
Hironaka, Katsuji
Yamamura, Masahiro
Yamaguchi, Yoshiyuki
|
| 著者所属(英) |
|
|
|
en |
|
|
Department of Clinical Oncology, Kawasaki Medical School |
| 著者所属(英) |
|
|
|
en |
|
|
Department of Clinical Oncology, Kawasaki Medical School |
| 著者所属(英) |
|
|
|
en |
|
|
Department of Clinical Oncology, Kawasaki Medical School |
| 著者所属(英) |
|
|
|
en |
|
|
Department of Clinical Oncology, Kawasaki Medical School |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Adoptive immunotherapy (AIT) |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Zoledronate |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Gammadelta T cells |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Cancer |
| 記事種別(日) |
|
|
内容記述タイプ |
Other |
|
内容記述 |
原著 |
| 抄録(英) |
|
|
|
en |
|
|
Adoptive immunotherapy (AIT) using autologous lymphocytes activated ex vivo with antigen stimulation, including zoledronate-activated killer (ZAK) cells, were conducted in the treatment of patients with incurable cancer. Efficacy, safety and treatment feasibility were all evaluated, retrospectively. Two-hundred and twenty-eight patients were enrolled and 198 were treated with AIT every 3 weeks. Success of effector cell generation was evident in 94.0% of the culture. A mean number of the administration was 6.8 times with a total number of 5.8 x 10^9 cells. Survival analysis implied marginal benefit of AIT in addition to chemotherapy in lung, colorectal, pancreatic cancers, especially in biliary cancer, showing the median survival time of 11.9 months. Objective tumor response of 3 CR and 6 PR was observed in colorectal, pancreatic, breast and biliary cancers, showing a response rate of 13.2%. Improvement of QOL was replied in 33% patients and FACT-BRM analysis demonstrated significant improvements in physical, social, emotional and functional well-beings. Together, it is suggested that AIT using autologous lymphocytes activated ex vivo with antigen stimulation, including ZAK cells, is safe and feasible, and may be effective in prolonging survival and improving QOL for patients with incurable cancer. |
| 書誌情報 |
en : Kawasaki medical journal
巻 40,
号 1,
p. 33-39,
発行日 2014
|
| URL |
|
|
識別子 |
http://igakkai.kms-igakkai.com/wp/wp-content/uploads/2014en/KMJ-E40(1)33.pdf |
|
識別子タイプ |
URI |
| DOI |
|
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.11482/KMJ-E40(1)33 |
| ISSN |
|
|
収録物識別子タイプ |
PISSN |
|
収録物識別子 |
0385-0234 |
| ISSN |
|
|
収録物識別子タイプ |
EISSN |
|
収録物識別子 |
2434-3404 |
| 雑誌書誌ID |
|
|
収録物識別子タイプ |
NCID |
|
収録物識別子 |
AA12685295 |
| 雑誌書誌ID |
|
|
収録物識別子タイプ |
NCID |
|
収録物識別子 |
AA12029005 |
| 著者版フラグ |
|
|
出版タイプ |
VoR |
KJ00009303679.pdf (210.3 kB)
